Johanna Friedl-Naderer net worth and biography

Johanna Friedl-Naderer Biography and Net Worth

Chief Commercial Officer of Dyne Therapeutics

Johanna brings more than two decades of biopharmaceutical industry experience in global commercialization including product launches in rare disease. She is dedicated to building high-performing, happy teams to bring innovative treatments to patients worldwide. Most recently Ms. Friedl-Naderer served as executive vice president and chief operating officer of Vir Biotechnology in the field of infectious disease. As president Europe, Canada & Partner Markets for Biogen, she led her team to successfully launch multiple specialty and rare disease products across 35 markets, impacting the lives of hundreds of thousands of patients. Ms. Friedl-Naderer was a member of Biogen’s global leadership team where she was accountable for the entire portfolio across therapeutic areas in her respective geographic region and managed a multibillion-dollar financial portfolio which doubled under her leadership. During her more than 20-year tenure at Biogen, she held positions of increasing responsibility across a wide range of functions, building and leading teams in advancing access to groundbreaking medicines for the treatment of devastating neurological conditions, including multiple sclerosis, SMA, ALS and Alzheimer’s disease. Ms. Friedl-Naderer has also served on several boards including the European Federation of Pharmaceutical Industries & Associations (EFPIA).

What is Johanna Friedl-Naderer's net worth?: The estimated net worth of Johanna Friedl-Naderer is at least $1.00 million as of March 13th, 2025. Ms. Friedl-Naderer owns 96,057 shares of Dyne Therapeutics stock worth more than $1,004,756 as of April 1st. This net worth estimate does not reflect any other assets that Ms. Friedl-Naderer may own. Learn More about Johanna Friedl-Naderer's net worth.
How do I contact Johanna Friedl-Naderer?: The corporate mailing address for Ms. Friedl-Naderer and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at ir@dyne-tx.com. Learn More on Johanna Friedl-Naderer's contact information.
Has Johanna Friedl-Naderer been buying or selling shares of Dyne Therapeutics?: Johanna Friedl-Naderer has not been actively trading shares of Dyne Therapeutics over the course of the past ninety days. Most recently, Johanna Friedl-Naderer sold 143 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $12.12, for a transaction totalling $1,733.16. Following the completion of the sale, the insider now directly owns 96,057 shares of the company's stock, valued at $1,164,210.84. Learn More on Johanna Friedl-Naderer's trading history.
Who are Dyne Therapeutics' active insiders?: Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Johanna Friedl-Naderer (Chief Commercial Officer), Susanna High (COO), Carlo Incerti (Director), Dirk Kersten (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.
Are insiders buying or selling shares of Dyne Therapeutics?: During the last year, Dyne Therapeutics insiders bought shares 1 times. They purchased a total of 32,000 shares worth more than $1,057,280.00. During the last year, insiders at the sold shares 25 times. They sold a total of 388,416 shares worth more than $12,878,411.80. The most recent insider tranaction occured on March, 13th when insider Johanna Friedl-Naderer sold 143 shares worth more than $1,733.16. Insiders at Dyne Therapeutics own 20.8% of the company. Learn More about insider trades at Dyne Therapeutics.
Information on this page was last updated on 3/13/2025.

Johanna Friedl-Naderer Insider Trading History at Dyne Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/13/2025	Sell	143	$12.12	$1,733.16	96,057

Johanna Friedl-Naderer Buying and Selling Activity at Dyne Therapeutics

Dyne Therapeutics Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $10.46

$9.96

$10.90

50 Day Range

MA: $13.20

$10.46

$16.76

2 Week Range

Now: $10.46

$9.96

$47.45

Volume

2,930,532 shs

Average Volume

1,376,040 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11